Fibromyalgia, Explained for the Person Who's Tired of Being Dismissed

This page is for the person who's cycled through Lyrica, Cymbalta, and Savella with diminishing returns. The person whose rheumatologist said they'd 'learn to manage it.' The person who's been told it's stress, told it's depression, told it's just how their body works now. The person who's spent years on the internet trying to find an explanation that fit, and kept finding the same recycled list of tender points and acceptance worksheets. The person who has been right, every time, to refuse those answers.

What you're about to read is the version of fibromyalgia education you should have gotten on day one.

What every fibromyalgia patient deserves to know

If you've been told fibromyalgia isn't a real condition, that you should try yoga, that you need to lose weight, that it's just stress, you can stop reading anywhere on this page that doesn't earn your trust. The medical system has been wrong about fibromyalgia for forty years. Here's what's actually happening.

Brain imaging proves the pain is biologically real. Gracely and colleagues (Arthritis & Rheumatism, 2002, n=32) ran functional MRI on women with fibromyalgia and pain-free controls. At equal-pressure stimulation, fibromyalgia patients showed activation in 13 brain regions. Controls showed activation in one. When the researchers backed off the pressure to match what each group reported as painful, the activation patterns became similar. That's the proof. The pain is real. The amplification is measurable. Your nervous system is generating pain through the exact brain regions pain-free people use to process pain, but with the volume turned far higher.

The IASP officially recognized your condition. In 2017, the International Association for the Study of Pain adopted 'nociplastic pain' as the third pain mechanism, alongside nociceptive pain (from injury) and neuropathic pain (from nerve damage). Fibromyalgia is the prototypical nociplastic pain condition. This is the IASP, the global authority on pain medicine, telling clinicians that fibromyalgia represents a distinct, real biological mechanism.

The WHO reclassified it. In 2022, the World Health Organization moved fibromyalgia into the ICD-11 chronic primary pain category. The ICD-11 framing is direct: in chronic primary pain, the pain itself is the disease. Not a symptom of something hidden. Not a psychiatric problem. The pain is the diagnosis.

The brain shows measurable changes. López-Solà and colleagues (Pain, 2017) developed a brain-based 'neurologic signature' that distinguishes fibromyalgia from controls with high sensitivity. Substance P levels run 2-3x normal in spinal fluid (Russell, 1998). Glutamate is elevated. Nerve growth factor is elevated. Microglia are activated. Jensen's 2012 paper showed fibromyalgia patients lack the descending pain inhibition that pain-free people use to dampen signals on their way to consciousness. This is not a normal nervous system mistakenly reporting pain. It's a sensitized nervous system generating real pain through real, observable biological changes.

The genetics are real and they are brain-based. The 2025 GWAS (2.5 million participants, 54,629 fibromyalgia cases) identified 26 risk loci and found that fibromyalgia heritability was 'exclusively enriched within brain tissues and neural cell types.' Not in muscles. Not in joints. Not in immune cells. Brain tissue. The single largest genetic study of fibromyalgia in history confirmed both that it's hereditary and that what's hereditary lives in the brain.

Here's what almost no one tells fibromyalgia patients. Those changes are not damage. They are learning. Your nervous system has learned a pain pattern. And learning, by definition, can be unlearned.

Why Lyrica, Cymbalta, and Savella keep losing effect

If you've been on a fibromyalgia medication for two years and the pain is back, you're not failing the medication. The medication is failing you. Here's why.

The three FDA-approved fibromyalgia medications (pregabalin/Lyrica, duloxetine/Cymbalta, milnacipran/Savella) all act on the central nervous system. They turn down the volume on pain signals. That's correct mechanism. Researchers in the 1990s and early 2000s recognized that fibromyalgia pain was centrally generated long before the IASP put 'nociplastic' in the official pain taxonomy. The drug companies designed medications around that hypothesis. They were aiming at the right target.

The problem is that these drugs treat the amplification without ever addressing what's causing the amplification. Your nervous system keeps learning. It keeps adjusting around the medication. The drug's effect plateaus. You add another. Doses creep up. Side effects accumulate. Lyrica produces the weight gain and the brain fog. Cymbalta runs into the famous discontinuation syndrome the second you try to taper. Savella raises your blood pressure. The cycle repeats.

The number of fibromyalgia patients who reach meaningful, durable relief from medication alone is small. Cochrane reviews of pregabalin, duloxetine, and milnacipran have all settled on a number-needed-to-treat between 6 and 10 for clinically meaningful benefit. That means for every 6 to 10 patients who try the drug, only one gets a result above placebo that they would actually call useful. Translation: roughly 90% of fibromyalgia patients fail to achieve meaningful relief from medications. The Cleveland Clinic Journal of Medicine wrote in 2023 that 'successful management begins with changing the thought process by educating patients about basic neuroanatomy, physiology, and the role of central sensitization.' That's the most-cited specialty journal in internal medicine telling its readers that the medications are not the answer.

There's a deeper reason these medications keep losing effect, and it's worth saying directly. The drugs target the volume itself. They don't teach the volume knob anything new. Your nervous system is a learning system. Learning systems re-tune around new inputs. When a Lyrica dose lowers your pain by 20%, your nervous system's threat-detection circuits notice and adjust upward to compensate. That's the physiology of habituation. It's the same reason your eyes adapt to a dark room and your nose adapts to a smell. The medication's signal becomes the new baseline, and the central sensitization keeps doing its job underneath.

This is the gap. The drugs were designed around the right hypothesis. They were just incomplete tools for that job. Turning down a volume knob is not the same as teaching the volume knob to settle. The brain-based therapies in the next section do the second thing. That's why their effects, in the trials, hold at 6 months, at 12 months, at 5 years. If your fibromyalgia is in this category, our 4-minute self-screener tells you whether the brain-based approach fits your specific pattern.

This is your call. You can keep doing what you've been doing. The medication route is honest. Some people do get meaningful help from it. Both/and is the right frame here, not either/or. Many people use medication to take the edge off while they retrain the underlying nervous-system pattern. What we'd ask you to consider is whether two more years of the same approach is the highest-probability path to feeling like yourself again. If the answer is no, the rest of this page is for you.

What's actually generating fibromyalgia pain

Your nervous system has a volume knob for pain. After enough time under stress, sleep deprivation, illness, trauma, or any combination of these, the volume knob gets stuck on high. Normal sensations from your muscles, your skin, your joints get amplified into pain. This is called central sensitization, and in fibromyalgia, it's not localized to one body region. It affects the whole sensory system, which is why fibromyalgia is widespread instead of localized.

The metaphor is Daniel Clauw's (the University of Michigan rheumatologist who's done more to translate the central-sensitization model into mainstream rheumatology than anyone). The volume-knob frame works for fibromyalgia better than for any other condition because fibromyalgia is, definitionally, the global version of the volume-knob problem. Other chronic-pain conditions have one region cranked up. Fibromyalgia has the whole sensory cortex cranked up.

Three things this explains that probably confused you before.

One, your pain spreads everywhere instead of staying in one place. Most chronic pain is localized because it started localized. A back pain patient feels it in their back. A TMJ patient feels it in their jaw. Fibromyalgia is widespread because the amplification is system-wide. Your pain moves around because the central nervous system generating it is one organ, not many. Pain in the shoulders this week, hips next week, hands the week after. Researchers have a name for this: migrating pain. It's a signature of central sensitization, not a sign that something is structurally wrong in each new location.

Two, sound, light, smell, and touch can all be too much. Fibromyalgia isn't just amplified pain. It's amplified sensory processing across the board. Roughly 76% of fibro patients have sensitivities to multiple sensory inputs (light, sound, smell, touch, temperature). That's the same volume knob, applied to the whole sensory system, not just the pain channel. When your husband's voice from the next room feels physically grating, that's not a personality flaw. That's the auditory cortex sharing the same upregulation that's driving your pain.

Three, your fatigue, brain fog, sleep disruption, and IBS came along with the pain. All of those symptoms are CNS-mediated. The same neurotransmitter imbalances driving pain (elevated glutamate, reduced serotonin, dopamine, norepinephrine) also regulate sleep, cognition, and energy. Your fatigue isn't a separate problem. It's the same problem in a different system. Sleep disruption, in particular, is a central feature: about 90% of fibromyalgia patients meet criteria for at least one sleep disorder. Moldofsky documented the characteristic alpha-delta sleep intrusion back in 1975. Your sleep isn't bad because of your pain. Your pain is partly worse because of your sleep. One night of lost sleep amplifies somatosensory pain responses by 126% (Krause, 2019). The sleep, the fatigue, the fog, and the pain are four expressions of the same central sensitization.

The mechanism, summarized. Your nervous system isn't broken. It's overprotective. The signals it's amplifying are real. The amplification is the problem, not the signals. And amplification is a learned pattern, which means it can be unlearned.

This is the deeper mechanism that drives fibromyalgia along with most other chronic primary pain conditions. We've written the full guide at central sensitization for readers who want the complete biological picture. If you also have TMJ pain, that's not a coincidence. The fibromyalgia-TMJ comorbidity odds ratio is 19.7. We've written the comprehensive TMJ guide for the same reason we've written this one. Same nervous system. Different region. Same recovery path.

How to recognize neuroplastic fibromyalgia in your own pain

Neuroplastic fibromyalgia shows up in patterns. Most fibromyalgia is neuroplastic, but pattern recognition gives you confidence in the call. If you check four or more of the items below, the brain-based explanation is the one to take seriously.

This isn't pattern matching for marketing. The Lumley 2017 trial and the Yarns 2024 trial both found that patients with higher psychological complexity, more comorbidities, and more entrenched fibromyalgia responded most strongly to the brain-based approaches. That's the opposite of what most psychological treatments show. It means the people most often dismissed by the medical system are the ones with the most to gain from this work.

What actually works for fibromyalgia

Fibromyalgia has been studied more thoroughly under brain-based therapy frameworks than any other chronic pain condition. The results are not subtle.

1. Emotional Awareness and Expression Therapy (EAET), the strongest single brain-based fibromyalgia evidence base. The Lumley 2017 trial (Pain) ran 230 women with fibromyalgia through a 3-arm randomized cluster trial: EAET, gold-standard CBT, or fibromyalgia education. Eight weekly 90-minute group sessions. The headline result is the cleanest single finding in the entire neuroplastic literature. 22.5% of EAET patients achieved 50% pain reduction. 8.3% of CBT patients did. EAET was roughly 2.7 times more effective than the gold-standard psychological treatment for fibromyalgia. Retention was 90.4%. Investigator allegiance was balanced because the EAET arm and the CBT arm were designed and delivered by separate teams. This was not a soft trial.

The Yarns 2024 trial (JAMA Network Open, n=126) replicated and extended that result in older veterans (mean age 71.9, 92% male, 55% Black, all with fibromyalgia or widespread chronic pain). 63% of the EAET group achieved at least 30% pain reduction. 17% of the CBT group did. The odds ratio was 21.5. The number-needed-to-treat for clinically significant pain reduction was about 2.2, meaning that for every two patients you treat with EAET instead of CBT, one additional patient gets meaningful relief. That's a treatment effect size mainstream medicine almost never sees in chronic pain.

The Yarns moderator finding deserves its own paragraph. Patients with higher baseline depression, anxiety, and PTSD responded MORE strongly to EAET, not less. This is the opposite of what standard psychological treatments show, where the more complicated patients tend to drop out and the cleaner cases drive the effect. The most psychologically complex fibromyalgia patients had the largest treatment advantage from EAET. That's the population most often dismissed by the medical system, and that's the population EAET worked best for.

2. Affective Self-Awareness (ASA), the brief Schubiner protocol. Hsu, Schubiner, and Lumley (Journal of General Internal Medicine, 2010, n=45) tested a brief affective self-awareness protocol against a wait-list control: one physician consultation plus three weekly 2-hour group sessions. Effect size at 6 months was d=1.46. That is a very large effect size by any standard, larger than what most pharmaceutical trials report. 45.8% of ASA patients achieved at least 30% pain reduction. 0% of wait-list controls did. Three sessions. Versus zero percent improvement in the wait-list group. Read that twice.

3. Pain Reprocessing Therapy (PRT), the first direct fibromyalgia trial. Sturgeon and colleagues (Regional Anesthesia & Pain Medicine, 2025, n=35) ran an open-label pilot of Brief PRT for fibromyalgia: just 3 telehealth sessions. Effect size d=0.89 for pain intensity at 3 months. Effect size d=1.06 for pain interference. 42.3% reported being 'much improved' or 'very much improved.' Completion rate was 94.3%. We'll be honest. This is preliminary. Small sample. No control group. But it's the first direct PRT-for-fibromyalgia trial, and it landed strong enough that a 150-patient replication is now underway. Watch this space.

4. PRT for chronic back pain, the closest analog. The Boulder Back Pain Study (Ashar et al., JAMA Psychiatry, 2022, n=151) found 66% of chronic back pain patients pain-free or nearly pain-free at 4 weeks versus 20% on placebo and 10% in usual care. The 5-year follow-up showed 55% remained pain-free. fMRI documented measurable quieting of the anterior insula and anterior midcingulate cortex, the two regions most implicated in chronic-pain amplification. We need to be direct: this was chronic back pain, not fibromyalgia. Fibromyalgia is a more entrenched form of central sensitization. The mechanistic transfer is sound. The magnitude shouldn't be assumed equal. Lumley and Schubiner's 2019 review in Current Rheumatology Reports lists fibromyalgia among the conditions expected to benefit, and the Sturgeon pilot is the first signal that the transfer works.

5. Pain Neuroscience Education. Teaching how pain works IS treatment. Louw and colleagues' 2016 systematic review found medium-to-large effect sizes on fear of movement and catastrophizing across multiple chronic pain populations. Education isn't placebo. It changes the brain's threat assessment, which is the upstream driver of central sensitization. The page you're reading right now is a part of that process. Reading the science, understanding the mechanism, and recognizing the pattern in your own pain is already shifting how your brain processes signals from your body. We've watched thousands of people walk through this.

The honest frame. About 35-45% of fibromyalgia patients show meaningful improvement on these approaches. About 20-25% achieve 50% pain reduction. Those rates match or exceed medication efficacy, with better durability and fewer side effects. Some patients don't respond. The Lumley 2017 trial saw about 65% of EAET patients not reach the 'much improved' threshold at 6 months. This isn't magic. It's biology, and biology has variance. If your fibromyalgia is driven by something else we haven't named yet, this approach won't fix it. The honesty is part of the case.

Where PainApp fits. PainApp applies the EAET, PRT, and PNE evidence to fibromyalgia in a self-guided format. The AI Pain Coach plus the F.I.T. Pain Tracker plus condition-specific somatic tracking adapted for the widespread, multi-symptom pattern of fibromyalgia. Curable lists fibromyalgia but isn't fibro-specific in its content. Stanza Mindset requires a prescription through Pear Therapeutics. Lin Health requires 1:1 coaching scheduling at $49-89 per month. PainApp is the brain-based fibromyalgia tool you can start tonight, on your schedule, for about a dollar a day. It's not the only path. It's the path designed for this condition specifically, and built so the cost isn't another barrier.

Your inflammation, your antibodies, your nerve fiber findings: what they actually mean

Fibromyalgia patients arrive with research findings that feel like they prove the condition is structural or autoimmune. Each one deserves a respectful answer, not dismissal. Let's go through them with the actual evidence.

'My CRP is elevated, so it must be inflammation.' Standard CRP and ESR are normal in fibromyalgia by classical definition. When high-sensitivity CRP shows mild elevation, a 2022 Oxford study found this is explained by BMI and physical inactivity, not the fibromyalgia itself. Only about 20% of fibromyalgia patients show any hsCRP elevation, and the elevations are sub-inflammatory. NSAIDs, the obvious treatment if inflammation were the driver, provide no proven benefit per Cochrane reviews. Mild hsCRP elevation in fibromyalgia is downstream of chronic pain (reduced activity, weight gain, stress hormones), not the cause. Your inflammation isn't lying. It's also not the source of your pain.

'Goebel 2021 proved fibromyalgia is autoimmune.' The Goebel study (Journal of Clinical Investigation) showed IgG antibodies from fibromyalgia patients can sensitize pain-processing neurons in the dorsal root ganglia of mice. This is a real, significant finding. What it actually shows is a mechanism by which central sensitization can develop in some patients, not that fibromyalgia is autoimmune in the classical sense. Goebel himself called it 'a new kind of autoimmunity, one which does not produce inflammation.' No systemic inflammation was detected. The mice recovered when the antibodies cleared. Reversibility supports the neuroplastic model. Subsequent work has found these antibodies in only a subset of fibromyalgia patients, and no common antibody target has been identified despite testing 42,000 peptides. The Goebel mechanism, where it applies, is one of the inputs that can drive central sensitization. The treatment target is still the central sensitization itself.

'I have small fiber neuropathy.' Roughly 20-49% of fibromyalgia patients show some small fiber neuropathy findings, depending on biopsy methodology. Which means 51-80% of fibromyalgia patients have full fibromyalgia symptoms with no SFN at all. The 2023 Dumolard study showed SFN findings in fibromyalgia are associated with central sensitization rather than directly causing the pain. Patients with SFN findings still respond to brain-based treatment, because the brain is what's amplifying and maintaining the pain regardless of whether peripheral nerve fiber density is reduced. Goebel's antibody work suggests SFN-like findings can develop within weeks of antibody exposure, positioning SFN as a downstream consequence of the same upstream process.

'Albrecht showed neuroinflammation.' Yes. Albrecht and colleagues (Brain, Behavior, and Immunity, 2019) showed elevated microglial activation in fibromyalgia patients on PET scans. The finding has replicated in 2021 and 2023. This is brain-level glial activation, not peripheral tissue inflammation. Glial activation is known to be triggered by psychological stress, sleep deprivation, and threat perception (Nijs, 2017). It's a central nervous system process fully compatible with the brain-generated pain model. Brain inflammation supports the central sensitization picture. It doesn't contradict it. The same Nijs paper proposed that sleep disturbances activate glial cells, creating neuroinflammation that increases CNS neuron excitability, which means sleep disruption may be one of the initiating factors for central sensitization in fibromyalgia.

'It runs in my family.' Fibromyalgia heritability is estimated at 48-54% from twin studies. The 2025 GWAS (2.5 million individuals, 54,629 fibromyalgia cases) identified 26 risk loci and found that 'fibromyalgia heritability was exclusively enriched within brain tissues and neural cell types,' not in muscles, joints, or immune cells. Strong genetic correlations were found with low back pain, PTSD, and IBS, the cluster of conditions central sensitization runs through. Translation: what runs in your family isn't a damaged muscle gene. It's a brain that's slightly more prone to learning and amplifying pain patterns. Genetics support the brain-based model. They're not an argument against it.

'I have fatigue and brain fog, not just pain.' Fatigue affects roughly 76% of fibromyalgia patients with significant intensity. Brain fog, sleep disruption, and chemical sensitivity are core features, not bonus problems. These are all CNS-mediated symptoms. The same neurotransmitter imbalances driving pain (elevated glutamate, reduced serotonin, dopamine, norepinephrine) also regulate sleep, cognition, and energy. Your fatigue isn't a separate problem. It's the same problem in a different system. When the central sensitization is addressed, all symptoms can improve together. That's why the EAET trials showed improvement on widespread pain AND on fatigue AND on functional measures, in the same patients, from the same intervention. One root. Many branches.

'My condition is more severe than most.' Fibromyalgia patients with the most severe, longest-duration, most-spreading pain show the strongest central sensitization markers, not the strongest evidence of structural damage. Severity is evidence FOR the neuroplastic explanation, not against it. The longer the pain has been there, the more entrenched the learned amplification pattern, and the more important it becomes to address that pattern directly. The Yarns 2024 finding (more depression, anxiety, and PTSD predicted greater EAET response, not less) is the same point in the data.

What fibromyalgia recovery actually looks like

Sarah is a composite story drawn from documented fibromyalgia recoveries in the published literature and in patient accounts collected by PainApp's editorial team. The arc is what we see repeatedly. Different ages, different trigger events, different cities. Same nervous-system pattern. Same recovery path.

Sarah's story is one. The Lumley trial saw 22.5% of fibromyalgia patients reach 50% pain reduction. The Yarns trial saw 35% reach 50%. The Hsu/Schubiner trial saw 45.8% reach 30% pain reduction in three sessions. Recovery isn't universal. It's also not rare. The pattern Sarah followed (somatic pattern recognition combined with fear reduction) is the same mechanism the EAET, ASA, and PRT trials operationalized.